References
- Bird RP (1987). Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Letts, 37, 147-51. https://doi.org/10.1016/0304-3835(87)90157-1
- Bojková B, Garajova M, Kajo K, et al (2010). Pioglitazone in chemically induced mammary carcinogenesis in rats. Eur J Cancer Prev, 19, 379-84. https://doi.org/10.1097/CEJ.0b013e32833ca233
- Bruce WR, Wolever TM, Giacca A (2000). Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr Cancer, 37, 19-26. https://doi.org/10.1207/S15327914NC3701_2
- Cowey S, Hardy RW (2006). The metabolic syndrome: A high-risk state for cancer? Am J Pathol, 169, 1505-22. https://doi.org/10.2353/ajpath.2006.051090
- Ferrara A, Lewis JD, Quesenberry CP Jr, et al (2011). Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care, 34, 923-9. https://doi.org/10.2337/dc10-1067
- Fisher B, Costantino JP, Wickerham DL, et al (1998). Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst, 90, 1371-88. https://doi.org/10.1093/jnci/90.18.1371
- Fukada T, Ohtani T, Yoshida Y, et al (1998). STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J, 17, 6670-7. https://doi.org/10.1093/emboj/17.22.6670
- Ikeda H, Taketomi S, Sugiyama Y, et al (1990). Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung, 40, 156-62.
- Itami A, Watanabe G, Shimada-Itami A, et al (2001). Ligands for peroxisome proliferator-activated receptorγ inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer, 94, 370-6. https://doi.org/10.1002/ijc.1488
- Iwaki M, Matsuda M, Maeda N, et al (2003). Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 52, 1655-63. https://doi.org/10.2337/diabetes.52.7.1655
- Kortylewski M, Heinrich PC, Mackiewicz A, et al (1999). Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene, 18, 3742-53. https://doi.org/10.1038/sj.onc.1202708
- Le Marchand L, Wilkens LR, Kolonel LN, et al (1997). Association of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res, 57, 4787-94.
- Nakamura M, Yamada K (1967). Studies on a diabetic (KK) strain of the mouse. Diabetologia, 3, 212-21. https://doi.org/10.1007/BF01222198
- Niho N, Mutoh M, Takahashi M, et al (2005). Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc Natl Acad Sci USA, 102, 2970- 4. https://doi.org/10.1073/pnas.0500153102
- Niho N, Takahashi M, Shoji Y, et al (2003). Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPARγ ligand. Cancer Sci, 94, 960-64. https://doi.org/10.1111/j.1349-7006.2003.tb01385.x
- Polyak K, Kato JY, Solomon MJ, et al (1994). p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factorbeta and contact inhibition to cell cycle arrest. Genes Dev, 8, 9-22. https://doi.org/10.1101/gad.8.1.9
-
Rumi MA, Sato H, Ishihara S, et al (2002). Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor
${\gamma}$ ligands. J Lab Clin Med, 140, 17-26. https://doi.org/10.1067/mlc.2002.125055 - Sakamoto J, Kimura H, Moriyama S, et al (2000). Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun, 278, 704-11. https://doi.org/10.1006/bbrc.2000.3868
- Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al (1996). PPARalpha and PPARgammma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J, 15, 5336-48.
- Schoonjans K, Staels B, Auwerx J (1996). The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta, 1302, 93-109. https://doi.org/10.1016/0005-2760(96)00066-5
- Shah P, Mudaliar S (2010). Pioglitazone: side effect and safety profile. Expert Opin Drug Saf, 9, 347-54. https://doi.org/10.1517/14740331003623218
- Shimada T, Kojima K, Yoshiura K, et al (2002). Characteristics of the peroxisome proliferators activated receptor gamma (PPAR gamma) ligand induced apoptosis in colon cancer cells. Gut, 50, 658-64. https://doi.org/10.1136/gut.50.5.658
- Sohda T, Momose Y, Meguro K, et al (1990). Studies on antidiabetic agents. Synthesis of hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung, 40, 37-42.
- Sporn MB, Suh N (2000). Chemoprevention of cancer. Carcinogenesis, 21, 525-30. https://doi.org/10.1093/carcin/21.3.525
- Takahashi N, Okumura T, Motomura W, et al (1999). Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett, 455, 135-9. https://doi.org/10.1016/S0014-5793(99)00871-6
- Teraoka N, Mutoh M, Takasu S, et al (2011). High susceptibility to azoxymethane-induced colorectal carcinogenesis in obese KK-Ay Mice. Int J Cancer, 102, 79-87.
- Turmelle YP, Shikapwashya O, Tu S, et al (2006). Rosiglitazone inhibits mouse liver regeneration. FASEB J, 20, 2609-11. https://doi.org/10.1096/fj.06-6511fje
- van Kruijsdijk RC, van der Wall E, Visseren FL (2009). Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev, 18, 2569-78. https://doi.org/10.1158/1055-9965.EPI-09-0372
- Xiao X, Wang Y, Gong H, et al (2009). Molecular evidence of senescence in corneal endothelial cells of senescenceaccelerated mice. Mol Vis, 15, 747-61.
Cited by
- allele promotes azoxymethane-induced colorectal carcinogenesis by macrophage migration in hyperlipidemic/diabetic KK mice vol.104, pp.7, 2013, https://doi.org/10.1111/cas.12162
- Type II Diabetes, Metformin Use, and Colorectal Neoplasia: Mechanisms of Action and Implications for Future Research vol.10, pp.1, 2014, https://doi.org/10.1007/s11888-013-0198-x
- Ubiquitination of p53 is Involved in Troglitazone Induced Apoptosis in Cervical Cancer Cells vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2313
- Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling vol.54, pp.12, 2014, https://doi.org/10.1002/mc.22231
- Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs vol.9, pp.2, 2016, https://doi.org/10.3390/ph9020024